The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy

Strahlenther Onkol. 2022 Sep;198(9):792-801. doi: 10.1007/s00066-022-01900-x. Epub 2022 Jan 24.

Abstract

Objective: The aim of the study was to assess the impact of clinical and metabolic parameters derived from 18F-FDG PET/CT (positron emission tomography-computed tomography) in patients with locally advanced cervical cancer (LACC) on prognosis.

Methods: Patients with LACC of stage IB2-IVA treated by primary radiochemotherapy followed by brachytherapy were enrolled in this retrospective study. Indexes derived from standardized uptake value (SUV), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and textural features of the primary tumor were measured for each patient. Overall survival (OS) and recurrence-free survival (RFS) rates were calculated according to Kaplan-Meier and survival curves were compared using the log-rank test. Uni- and multivariate analyses were performed using the Cox regression model.

Results: A total of 116 patients were included. Median follow-up was 58 months (range: 1-129). A total of 36 (31%) patients died. Five-year OS and RFS rates were 69 and 60%, respectively. Univariate analyses indicated that FIGO stage, the presence of hydronephrosis, high CYFRA 21.1 levels, and textural features had a significant impact on OS and RFS. MTV as well as SCC-Ag concentration were also significantly associated with OS. On multivariate analysis, the presence of hydronephrosis, CYFRA 21.1, and sphericity were independent prognostics factors for OS and RFS. Also, SCC-Ag level, MTV, and GLZLM (gray-level zone length matrix) ZLNU (zone length non-uniformity) were significantly associated with OS.

Conclusion: Classical prognostic factors and tumor heterogeneity on pretreatment PET/CT were significantly associated with prognosis in patients with LACC.

Keywords: Chemoradiotherapy; Positron emission tomography–computed tomography; Prognosis; Uterine cervical neoplasms.

MeSH terms

  • Antigens, Neoplasm
  • Chemoradiotherapy
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Hydronephrosis*
  • Keratin-19
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography
  • Prognosis
  • Radiopharmaceuticals
  • Retrospective Studies
  • Tumor Burden
  • Uterine Cervical Neoplasms* / diagnostic imaging
  • Uterine Cervical Neoplasms* / metabolism
  • Uterine Cervical Neoplasms* / therapy

Substances

  • Antigens, Neoplasm
  • Keratin-19
  • Radiopharmaceuticals
  • antigen CYFRA21.1
  • Fluorodeoxyglucose F18